Aqr Capital Management LLC Affimed N.V. Transaction History

Aqr Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $681,619 - $897,402	-126,931 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $465,492 - $631,020	84,024 Added 195.83%	126,931 $784,000
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $111,285 - $163,065	14,304 Added 50.01%	42,907 $365,000
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $191,923 - $317,872	-37,485 Reduced 56.72%	28,603 $226,000
Q4 2020 Feb 16, 2021	SELL	$3.16 - $7.03 $418,007 - $929,935	-132,281 Reduced 66.68%	66,088 $385,000
Q3 2020 Nov 16, 2020	SELL	$3.26 - $4.73 $1.07 Million - $1.55 Million	-327,840 Reduced 62.3%	198,369 $672,000
Q2 2020 Aug 17, 2020	SELL	$1.58 - $4.63 $903,248 - $2.65 Million	-571,676 Reduced 52.07%	526,209 $2.43 Million
Q1 2020 May 15, 2020	BUY	$1.44 - $3.02 $50,391 - $105,681	34,994 Added 3.29%	1,097,885 $1.74 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $378,927 - $517,024	168,412 Added 18.83%	1,062,891 $2.91 Million
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $2.39 Million - $3.26 Million	894,479 New	894,479 $2.63 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.